Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target
Johnson & Johnson closed its $3.05 billion acquisition of Halda Therapeutics, saying the deal will cut adjusted EPS by $0.20 between late 2025 and 2026. JNJ shares edged up 0.02% to $206.95 as the S&P 500 fell 0.74% on the year’s final trading day. Barclays raised its price target to $217, maintaining an Equal Weight rating. The company will discuss its 2026 outlook on Jan. 21.